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Escherichia coli sequence type ST131 (fromphylogenetic groupB2), often carrying the extended-spectrum--lactamase (ESBL) gene
blaCTX-M-15, is an emerging globally disseminated pathogen that has received comparatively little attention in theUnited States. Ac-
cordingly, a convenience sample of 351 ESBL-producing E. coli isolates from15U.S. centers (collected in 2000 to 2009) underwent
PCR-based phylotyping anddetection of ST131 and blaCTX-M-15. A total of 200 isolates, comprising 4 groups of 50 isolates each that
were (i) blaCTX-M-15 negative non-ST131, (ii) blaCTX-M-15 positive non-ST131, (iii) blaCTX-M-15 negative ST131, or (iv) blaCTX-M-15 posi-
tive ST131, also underwent virulence genotyping, antimicrobial susceptibility testing, and pulsed-field gel electrophoresis (PFGE).
Overall, 201 (57%) isolates exhibited blaCTX-M-15, whereas 165 (47%)were ST131. ST131 accounted for 56%of blaCTX-M-15-positive-
versus 35%of blaCTX-M-15-negative isolates (P< 0.001).Whereas ST131 accounted for 94%of the 175 total groupB2 isolates, non-
ST131 isolateswere phylogenetically distributed by blaCTX-M-15 status, with groupsA (blaCTX-M-15-positive isolates) andD (blaCTX-M-15-
negative isolates) predominating. Both blaCTX-M-15 and ST131 occurred at all participating centers, were recovered fromchildren and
adults, increased significantly in prevalence post-2003, andwere associatedwithmolecularly inferred virulence. Comparedwith non-
ST131 isolates, ST131 isolates had higher virulence scores, distinctive virulence profiles, andmore-homogeneous PFGEprofiles.
blaCTX-M-15 was associatedwith extensive antimicrobial resistance and ST131with fluoroquinolone resistance. Thus, E. coli ST131 and
blaCTX-M-15 are emergent, widely distributed, and predominant among ESBL-positive E. coli strains in theUnited States, among chil-
dren and adults alike. Enhanced virulence and antimicrobial resistance have likely promoted the epidemiological success of these
emerging public health threats.
Extraintestinal Escherichia coli infections, including urinary tractinfections, sepsis, and neonatal meningitis, are important causes
of morbidity, mortality, and increased health care costs (26). Their
management is increasingly challenging due to the rising prevalence
of resistance to first-line antimicrobial agents, including fluoro-
quinolones and extended-spectrum cephalosporins (14, 23). Con-
tributing significantly to this increase is a recently emerged E. coli
lineage designated sequence type ST131, which is characterized as
belonging toserotypeO25:H4and isassociatedwithfluoroquinolone
resistance and CTX-M-15, an IncFII-plasmid-mediated extended-
spectrum -lactamase (ESBL) (21, 25).
The initial reports in 2008 of E. coli ST131 as an important new
pathogen involved isolates from diverse non-U.S. international
locales (3, 5, 18). Subsequently, case reports and small series doc-
umented the presence of ST131 also in the United States, with the
ESBL-positive ST131 isolates usually producing CTX-M-15 (6, 7,
9, 11, 17, 20, 27, 29, 30). The only published large-scale survey to
date for ST131 in the United States appeared in 2010 and was
based on clinical isolates from 2007 from two national surveil-
lance programs (8). There, ST131 accounted for approximately
two-thirds of all ESBL-positive or fluoroquinolone-resistant E.
coli study isolates, with 73% of ESBL-positive ST131 isolates ex-
hibiting CTX-M-15 (8).
Limitations of that study included the single study year, restric-
tions with respect to the participating sites and selection criteria of
the surveillance systems, and inclusion of only 59 total ESBL-pos-
itive isolates (8). Here we assessed the reproducibility of that sur-
vey’s findings and explored new associations, using a 10-year
study period and a much larger population that included isolates
from both children and adults.
MATERIALS AND METHODS
Strains. The 351 ESBL-positive E. coli study isolates, including some pre-
viously published isolates (16, 17, 27, 29), were obtained as a series of
convenience samples from colleagues at 15 research or clinical laborato-
ries across the United States (Table 1). Each center was invited to submit all
available E. coli clinical isolates thatmet the study criteria, including (i) isola-
tion from 2000 to 2009 and (ii) confirmed ESBL production according to
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Clinical and Laboratory Standards Institute (CLSI) criteria (4). Upon receipt
in the study laboratory, all isolates were screened for blaCTX-M-15 by PCR (as
described below). All blaCTX-M-15 PCR-negative isolates were further
screened by disk diffusion for extended-spectrum-cephalosporin susceptibil-
ity (as described below). All extended-spectrum-cephalosporin-susceptible
isolates so identified were further screened for ESBL production, using cefo-
taxime and ceftazidime disks with or without clavulanate (4). For study in-
clusion, isolates were required to be blaCTX-M-15 positive or, if blaCTX-M-15
negative, to be either extended-spectrum cephalosporin resistant or (if re-
tested) to exhibit an ESBL phenotype.
Detection of blaCTX-M-15. The PCR screen for blaCTX-M-15 involved a
combination of published and newly devised primers. After an initial screen
using primers that detect blaCTX-M-15 plus related blaCTX-M variants (15),
PCR-positive isolates were retested using a novel extended “CTX-M-15-spe-
cific” forward primer (15extF [ATAAAACCGGCAGCGGTGG]), which
hybridizes with blaCTX-M-15 and, per the data shown at http://www.lahey
.org/Studies/other.asp#table1, with several other group 1 blaCTX-M vari-
ants (including blaCTX-M-28, -29, 3-3, -53, -82 but not blaCTX-M-1, blaCTX-M-3,
or several other blaCTX-M-3-like variants detected by the blaCTX-M-15
screening primers). They also were retested using a novel extended “CTX-
M-3-specific” forward primer (3extF [ATAAAACCGGCAGCGGTGA]),
which hybridizes with blaCTX-M-3 and a different set of group 1 blaCTX-M
variants (including blaCTX-M-1, -10, -11, -12, -22, -23, -30, -32, -34, -36, -37, -42, -52).
Isolates reacting with the extended blaCTX-M-15 primer but not the extended
blaCTX-M-3 primerwere further screenedusing anovelblaCTX-M-28-specific for-
ward primer (28for [GGTTAAAAAATCACTGCGT]), in combination
with CTX-M group 1 reverse primer M13L (15), since blaCTX-M-28 is the
most frequent of the potential cross-reacting blaCTX-M variants.
Conditions for the novel PCRs were largely as described elsewhere
(13). Reaction mixtures included 1 buffer, 4 mM MgCl2, 0.8 mM de-
oxynucleoside triphosphate (dNTP) mix, 1.25 U of AmpliTaq Gold, 0.6
Mspecific primers, 2.0l of boiled lysate DNA, andH2O to reach a final
volume of 25l. Cycling was performed as follows: 95°C activation for 10
min; 25 cycles of 30 s of denaturation at 94°C and then 3min of annealing
and extension at 76°C (for blaCTX-M-15 and blaCTX-M-3 PCR [amplicon,
483 bp]) or at 68°C (for blaCTX-M-28 PCR [amplicon, 863 bp]); 10= exten-
sion at 72°C; and then a hold at 4°C. Isolates that gave positive test results
with the initial and extended blaCTX-M-15 primers but negative test results
with the blaCTX-M-3 and blaCTX-M-28 primers were regarded as blaCTX-M-15
positive.
Validation of this tiered PCR approach using 257 reference isolates
containing sequenced blaCTX-M variants (181 reportedly blaCTX-M-15, 76
reportedly non-blaCTX-M-15) yielded only 9 discrepancies, all but three of
which were resolved in favor of the PCR results by repeat PCR and se-
quencing. The persisting discrepancies involved 3 blaCTX-M-53-positive
isolates that were falsely identified by PCR as containing blaCTX-M-15,
consistent with the predicted cross-reactivity of blaCTX-M-15 primers with
the (rarely encountered) blaCTX-M-53 variant. This yielded an estimated
overall accuracy rate of 98.8% (95% confidence interval, 96.6% to 99.8%)
for detection of blaCTX-M-15 by tiered PCR.
Phylogenetic group and ST131 status. Themajor E. coli phylogenetic
groups (A, B1, B2, and D) were determined by triplex PCR (1). ST131
isolates were identified by PCR-based detection of ST131-specific single-
nucleotide polymorphisms (SNPs) inmdh and gyrB (10). Seventeen ran-
domly selected presumptive ST131 isolates underwent confirmatory 7-lo-
cus multilocus sequence typing (MLST) based on partial sequences for
adk, fumC, gyrB, icd, mdh, purA, and recA (http://mlst.ucc.ie/mlst/dbs
/Ecoli); all were confirmed as ST131. All isolates were screened by PCR for
ST131-associated traits, including the F10 papA allele (P-antigen-recog-
nizing fimbria [P fimbria] structural subunit variant) and the O25b rfb
(lipopolysaccharide synthesis) variant (2, 10).
Antimicrobial susceptibility. A total of 200 isolates, comprising 4
groupsof50randomlyselected isolates each thatwere (i)blaCTX-M-15negative
non-ST131; (ii) blaCTX-M-15 positive non-ST131; (iii) blaCTX-M-15 negative
ST131; or (iv) blaCTX-M-15-positive ST131 underwent additional testing. An-
timicrobial susceptibility to 21 agents was determined by disk diffusion using
TABLE 1 Sources and ST131 and blaCTX-M-15 status of 351 extended-spectrum--lactamase-producing Escherichia coli isolates collected in the
United States in 2000 to 2009
City or center source
(reference, if published)
Yr of
isolation
Patient
population
Total
no. of
isolates
No. (%) of isolates in indicated categorya,b
No. of ST131 isolates/total
no. of isolates (%)aTrait Subseta,b
M15 ST131
ST131
M15
ST131
M15
ST131
M15
ST131
M15 M15 M15
Miami, FL 2009 Adultsc 23 19 (83) 7 (30) 1 (4) 15 (65) 3 (13) 4 (17) 3/4 (75) 4/19 (21)
Chicago, IL 2007–2008 Adults 8 6 (75) 5 (63) 1 (13) 2 (25) 1 (13) 4 (50) 1/2 (50) 4/6 (67)
Evanston, IL 2007 Adults 27 16 (59) 17 (63) 4 (15) 6 (22) 7 (26) 10 (37) 7/11 (64) 10/16 (63)
Portland, ME 2008 Adult 1 1 (100) 1 (100) 0 (0) 0 (0) 0 (0) 1 (100) (none) 1/1 (100)
Minneapolis, MN (Hennepin
County Medical Center)
2008–2009 Adults 31 17 (55) 17 (55) 9 (29) 5 (16) 5 (16) 12 (39) 5/14 (36) 12/17 (71)
Minneapolis, MN
(Children’s Hospital)
2002–2009 Children 33 12 (36) 12 (36) 16 (48) 5 (15) 5 (15) 7 (21) 5/21 (24) 7/12 (58)
St. Paul, MN 2007–2008 Adults 20 12 (60) 7 (35) 5 (25) 8 (40) 3 (15) 4 (20) 3/8 (38) 4/12 (33)
Winston-Salem, NC 2008–2009 Adults 11 8 (73) 8 (73) 3 (27) 0 (0) 0 (0) 8 (73) 0 (0) 8/8 (100)
Omaha, NE 2005 Adults 4 1 (25) 2 (50) 2 (50) 0 (0) 1 (25) 1 (25) 1/3 (33) 1/1 (100)
Philadelphia, PA (17) 2007 Adults 31 14 (45) 15 (48) 10 (32) 6 (19) 7 (23) 8 (26) 7/17 (41) 8/14 (57)
Pittsburgh, PA (27) 2006–2007 Adults 17 7 (41) 10 (59) 5 (29) 2 (12) 5 (29) 5 (29) 5/10 (50) 5/7 (71)
New York City (Queens),
NY (29)
2004–2008 Adult 63 37 (59) 38 (60) 15 (24) 10 (16) 11 (17) 27 (43) 11/26 (42) 27/37 (73)
Houston, TX (30) 2004–2009 Adults 38 30 (79) 10 (26) 7 (18) 21 (53) 1 (3) 9 (24) 1/8 (13) 9/30 (30)
San Antonio, TX (16) 2000–2006 Adults 20 11 (55) 7 (35) 7 (35) 6 (30) 2 (10) 5 (25) 2/9 (22) 5/11 (45)
Seattle, WA 2004–2007 Childrend 24 10 (42) 9 (38) 13 (54) 2 (8) 1 (4) 8 (33) 1/14 (7) 8/10 (80)
Total 2000–2009 Mixed 351 201 (57) 165 (47) 97 (28) 89 (25) 51 (15) 114 (33) 51/148 (34) 114/203 (56)
a M15, positive for blaCTX-M-15; M15
, negative for blaCTX-M-15.
b ST131, ST131 sequence type; ST131, non-ST131 sequence type.
c Includes 1 pediatric isolate.
d Includes 1 adult isolate.
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Clinical and Laboratory Standards Institute (CLSI)-specified procedures,
control strains, and (2011) interpretive criteria. Agents tested included ami-
kacin (AMK), ampicillin (AMP), amoxicillin-clavulanate (AML), aztreonam
(ATM), cefepime (FEP), ceftazidime (CAZ), ceftriaxone (CRO), cephalothin
(KF), chloramphenicol (C), ciprofloxacin (CIP), gentamicin (CN), imi-
penem(IMP),nalidixic acid (NA),nitrofurantoin (F), piperacillin (PIP),pip-
eracillin-tazobactam (TZP), streptomycin (S), sulfonamides (SF), tetracy-
cline (TE), trimethoprim (W), and trimethoprim-sulfamethoxazole (SXT).
Intermediate results were analyzed as representing resistance. The resistance
score represented the number of agents to which an isolate was resistant,
excluding SXT (due to redundancy with SF andW).
Extended virulence genotypes. The 200 isolates were tested for the
presence of 50 extraintestinal pathogenic E. coli (ExPEC)-associated vir-
ulence genes and housekeeping gene uidA (-glucuronidase) by multi-
plex PCR (10). Isolates were defined as ExPEC if positive for2 of papA
and/or papC (P fimbria major subunit and assembly), sfa/focDE (S and
F1C fimbriae), afa/draBC (Dr-binding adhesins), kpsM II (group 2 cap-
sule), and iutA (aerobactin receptor) (12). The virulence score repre-
sented the number of virulence genes detected, adjusted for multiple de-
tection of the pap, sfa, foc, and kpsM II operons.
PFGE analysis. The 200 isolates underwent pulsed-field gel electro-
phoresis (PFGE) analysis of XbaI-restricted total DNA per the PulseNet
protocol (24). By using BioNumerics (Applied Maths) and band-based
Dice similarity coefficients, pulsotype designations were assigned at the
94% profile similarity level, corresponding to an approximately 3-band
difference (28).
Statistical methods. Comparisons of proportions were tested using
Fisher’s exact test (two-tailed) or a chi-square test if unpaired andMcNe-
mar’s test if paired. Comparisons of virulence scores were tested using the
Mann-Whitney U test (two-tailed). To simplify the virulence genotype
and antimicrobial susceptibility data for comparisons among the four
subgroups as defined by combined CTX-M-15 status and ST131 status,
principal coordinate analysis (PCoA) was performed using GENALEX 6
software (19). This multidimensional scaling method captures within the
first 2 axes most of the total variance contained in a multivariable, multi-
specimen data set. Analysis of molecular variance (AMOVA) was used to
determine the percentage of diversity within populations versus among
populations (19).
RESULTS
Origins of isolates. The 351 ESBL-producing E. coli study isolates
were from 15 centers distributed broadly across the United States
(Table 1). Centers contributed amedian of 23 isolates each (range,
1 to 63 isolates). Years of isolation ranged from 2000 to 2009
(median, 2007). Source patients included both adults (n  295
[84%]) and children (n  57 [16%]). Additional clinical data,
including specimen type, were unavailable.
CTX-M-15 and ST131 status. According to tiered PCR-based
testing, 201 (57%) of the 351 study isolates contained CTX-M-15
(median per center, 59%; range, 25% to 100%), whereas 165
(47%) represented ST131 (median per center, 50%; range, 26% to
100%) (Table 1). Overall, ST131 was statistically significantly as-
sociated with CTX-M-15, accounting for 56% of CTX-M-15-pos-
itive isolates versus 34% of CTX-M-15-negative isolates (P 
0.001). This trend was evident at 12 of the 15 individual centers,
including both children’s hospitals (Table 1).
The 4 possible combinations of ST131 status and CTX-M-15
status defined 4 subgroups (Table 1). Of these, the dual-positive
subgroup (i.e., ST131 CTX-M-15) was the most prevalent
(33%), followed sequentially by the ST131 CTX-M-15 sub-
group (28%), the ST131 CTX-M-15 subgroup (25%), and the
ST131 CTX-M-15 subgroup (15%) (Table 1). All but three
centers contributed one or more representatives of each of these 4
subgroups, and the 3 centers that did not do so provided only 1 to
11 isolates each.
CTX-M-15 and ST131 versus phylogenetic group, F10 papA
allele, andO25b rfb variant. In the total population, groupB2was
the dominant phylogenetic group, accounting for 50% of isolates,
followed sequentially in prevalence by groups D (25%), A (18%),
and B1 (7%) (Table 2). Whereas by definition the ST131 isolates
were all from group B2, regardless of CTX-M-15 status, the non-
ST131 isolates were least likely to be from group B2 (versus other
groups), and their phylogenetic group distribution varied signifi-
cantly with CTX-M-15 status. That is, the CTX-M-15-negative
non-ST131 isolates were predominantly from group D, followed
by groups B1, A, andB2. In contrast, theCTX-M-15-positive non-
ST131 isolates were predominantly from group A, followed by
groups D and B1, with none from group B2.
The F10 papA allele and O25 rfb variant were significantly more
prevalent among ST131 isolates than non-ST131 isolates, regardless
of CTX-M-15 status (Table 1). Additionally, for the ST131 isolates,
the F10 papA allele was significantlymore prevalent amongCTX-M-
15-positive than CTX-M-15-negative isolates, although the absolute
difference was modest (81% versus 97%) (Table 1).
CTX-M-15 and ST131 versus year of isolation. When ana-
lyzed as a continuous variable, the year of isolation was borderline
TABLE 2 Characteristics of 351 extended-spectrum--lactamase-producing Escherichia coli clinical isolates from the United States, 2000 to 2009
Characteristica
No. (%) of isolatesb
P valuec
Total
(n 351)
Subset
ST131M15
(group 1; n 98)
ST131M15
(group 2; n 89)
ST131M15
(group 3; n 52)
ST131M15
(group 4; n 113)
Group 1
vs 2
Group 3
vs 4
Group 1
vs 3
Group 2
vs 4
Group A 63 (18) 17 (17) 46 (52) 0 (0) 0 (0)  0.001 0.001  0.001
Group B1 24 (7) 20 (20) 4 (5) 0 (0) 0 (0) 0.002  0.001 0.035
Group B2 175 (50) 10 (10) 0 (0) 52 (100) 113 (100) 0.002  0.001  0.001
Group D 89 (25) 51 (52) 38 (43) 0 (0) 0 (0)  0.001  0.001
F10 papA allele 168 (48) 9 (9) 8 (9) 42 (81) 109 (97) 0.002  0.001  0.001
O25b rfb allele 159 (45) 0 (0) 0 (0) 48 (92) 110 (97)  0.001  0.001
Post-2003 origin 338 (96) 89 (91) 85 (97) 51 (98) 113 (100) 0.10 0.08
a Group, major E. coli phylogenetic group; F10 papA allele, P fimbria structural subunit variant; O25b rfb allele, O25 lipopolysaccharide synthesis.
b M15, positive for blaCTX-M-15; M15
, negative for blaCTX-M-15; ST131
, ST131 sequence type; ST131, non-ST131 sequence type.
c P values (by Fisher’s exact test; two-tailed) are shown where P 0.10. For all variables, an initial 4-group comparison yielded P 0.003.
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significantly more recent for CTX-M-15-positive isolates than
CTX-M-15-negative isolates (P  0.099) and for ST131 isolates
than non-ST131 isolates (P 0.053). The distribution of isolation
years by CTX-M-15 and ST131 status suggested that, for both
variables, 2003 to 2004 would be the optimal breakpoint for di-
chotomous stratification (not shown). With the years categorized
using this breakpoint, CTX-M-15 and ST131 were both signifi-
cantly more prevalent among isolates from 2004 to 2009 than
among those from 2000 to 2003 (for CTX-M-15, 77% versus 23%
[P  0.019]; for ST131, 49% versus 8% [P  0.004]), consistent
with the emergence of both traits over the decade.
Among the four subgroups defined by combined CTX-M-15
status and ST131 status, the proportion of isolates from 2004 to
2009 (versus isolates from 2000 to 2003) increased progressively
across subgroups, from a low of 91% (CTX-M-15-negative, non-
ST131 isolates) to a high of 100% (CTX-M-15-positive, ST131
isolates) (P  0.003 for the 4-group comparison) (Table 2). In
pairwise comparisons among the 4 subgroups, ST131 isolates
were borderline significantly more likely than non-ST131 isolates
to be from 2004 to 2009, regardless of CTX-M-15 status (Table 2).
Extended virulence genotypes.Genotypes for 51ExPEC-asso-
ciated virulence markers were determined for 50 randomly se-
lected representatives per subgroup for the 4 subgroups as defined
by CTX-M-15 status and ST131 status (total n  200). The se-
lected isolates exhibited the same phylogenetic group distribution
as their respective source subgroups, evidence that they were a
representative subset (Table 3). All but 8 of the virulence markers
sought were detected in 1 isolate each, with 18 (42%) of the
TABLE 3 Molecular characteristics of 200 selected extended-spectrum--lactamase-producing Escherichia coli isolates (collected in 2000 to 2009) in
relation to ST131 and blaCTX-M-15 status
Trait categorya,b Specific traita
No. (%) of isolates P valuec
ST131M15
(group 1; n 50)
ST131M15
(group 2; n 50)
ST131M15
(group 3; n 50)
ST131M15
(group 4; n 50)
Group 1
vs 2
Group 3
vs 4
Group 1
vs 3
Group 2
vs 4
Phy. group Group A 10 (20) 28 (56) 0 (0) 0 (0) 0.001 0.001 0.001
Group B1 7 (14) 1 (2) 0 (0) 0 (0) 0.01
Group B2 5 (10) 0 (0) 50 (100) 50 (100) 0.001 0.001
Group D 28 (56) 21 (42) 0 (0) 0 (0) 0.001 0.001
Adhesins F10 papA 4 (8) 5 (10) 40 (80) 50 (100) 0.001 0.001 0.001
afa/draBC 3 (6) 2 (4) 2 (4) 13 (26) 0.03 0.004
iha 8 (16) 3 (6) 39 (78) 48 (96) 0.02 0.001 0.001
fimH 42 (84) 30 (60) 50 (100) 50 (100) 0.01 0.006 0.001
hra 10 (20) 6 (12) 1 (2) 4 (8) 0.008
Toxins sat 6 (12) 3 (6) 39 (78) 48 (96) 0.02 0.001 0.001
vat 6 (12) 0 (0) 1 (2) 0 (0) 0.03
astA 9 (18) 5 (10) 0 (0) 0 (0) 0.03
Siderophores fyuA 30 (60) 31 (62) 49 (98) 50 (100) 0.001 0.001
iutA 21 (42) 39 (78) 43 (86) 49 (98) 0.001 0.001 0.001
Capsule kpsM II 18 (36) 11 (22) 35 (70) 45 (90) 0.02 0.001 0.001
K2 3 (6) 4 (8) 5 (10) 17 (34) 0.007 0.003
K5 3 (6) 0 (0) 20 (40) 18 (36) 0.001 0.001
kpsMT III 3 (6) 9 (18) 0 (0) 0 (0) 0.003
Miscellaneous usp 7 (14) 1 (2) 49 (98) 50 (100) 0.001 0.001
ompT 15 (30) 7 (14) 48 (96) 50 (100) 0.001 0.001
traT 34 (68) 42 (84) 44 (88) 46 (92) 0.03
malX 17 (34) 20 (40) 48 (96) 50 (100) 0.001 0.001
ExPEC n.a.d 15 (30) 7 (14) 33 (66) 47 (94) 0.001 0.001 0.001
PFGE statuse 2 per type 9 (19)f 22 (44) 27 (54) 41 (82) 0.009 0.005 0.001 0.001
5 per type 0 (0) 0 (0) 18 (36) 33 (66) 0.001 0.001
a Traits shown are those that yielded P 0.05 in an initial four-way comparison (not shown) plus at least one pairwise comparison (as shown). These included afa/draBC (Dr-
binding adhesins), astA (enteroaggregative E. coli heat-stable toxin), the F10 papA allele (P fimbria structural subunit variant), fimH (type 1 fimbria adhesin), fyuA (yersiniabactin
system), hra (heat-resistant agglutinin), iha (adhesin siderophore), iutA (aerobactin system), K2 (group 2 capsule variant), K5 (group 2 capsule variant), kpsMII (group 2 capsule),
kpsMTIII (group 3 capsule),malX (fitness island marker), ompT (outer membrane protease), sat (secreted autotransporter toxin), usp (uropathogenic specific protein), and vat
(vacuolating toxin). Traits detected in1 isolate but without significant by-group prevalence differences (definition: overall prevalence) included afaE8 (afimbrial adhesin: 1.5%),
bmaE (M fimbriae: 1.5%), cdtB (cytolethal distending toxin B: 0.5%), clbB and clbN (polyketide synthesis: 1% and 2%), clpG (mannose-resistant adhesin: 0.5%), cnf1 (cytotoxic
necrotizing factor: 2%), cvaC (microcin V: 1%), H7 fliC allele (flagellin: 0.5%), hlyD (alpha hemolysin: 3.5%), hlyF (hemolysin variant: 4%), ibeA (invasion of brain endothelium:
2%), ireA (siderophore receptor: 1.5%), iroN (salmochelin receptor: 3%), iss (increased serum survival: 3%), K1 (capsule variant: 3%), papAH (P fimbria major subunit: 4.5%),
papC (P fimbria assembly: 7.0%), papEFG (P fimbria tip pilins: 5.5%), papG alleles II and III (P adhesin variants: 4.5% and 1%), pic (autotransporter protease: 0.5%), rfc (O4
lipopolysaccharide synthesis: 1%), traT (serum resistance associated: 82.5%), and tsh (temperature-sensitive hemagglutinin: 2%). Traits sought but not detected included F17
(mannose-resistant adhesin), focG (F1C adhesin), gafD (G fimbriae), K15 (capsule variant), papG allele I (P adhesin variant), pic (protein associated with intestinal colonization),
sfa/foc (S and F1C fimbriae), and sfaS (S fimbria adhesin).
b ExPEC, extraintestinal pathogenic E. coli; PFGE, pulsed-field gel electrophoresis; Phy., phylogenetic. ExPEC was defined as the presence of2 of papA and/or papC and of sfa/foc,
afa/dra, kpsMII, and iutA.
c P values (by Fisher’s exact test, two-tailed) are shown where P 0.05.
d n.a., not applicable.
e The data correspond to isolates belonging to pulsotype groups consisting of2 isolates or5 isolates each.
f The denominator was 48 (rather than 50), since 2 isolates were refractory to XbaI PFGE analysis.
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detectedmarkers exhibiting a significant between-subgroup prev-
alence difference in relation to CTX-M-15 status, ST131 status, or
both (Table 3).
Several general trends were apparent from these differences
(Table 3). First, statistically significant prevalence differences were
more than twice as frequent in relation to ST131 status as they
were in relation to CTX-M-15 status. Second, whereasmost of the
ST131 versus non-ST131 prevalence differences favored the
ST131 isolates (e.g., for the F10 papA allele, afa/dra, iha, fimH, sat,
fyuA, kpsMII, K2, K5, usp, ompT, traT, andmalX), several favored
the non-ST131 isolates (e.g., for hra, astA, and kpsMT III). Third,
whereas quite similar sets of genes exhibited ST131-associated
prevalence differences among CTX-M-15-positive compared
with CTX-M-15-negative isolates, distinct sets of genes exhibited
CTX-M-15-associated prevalence differences among ST131 iso-
lates compared with non-ST131 isolates.
Consistent with the greater prevalence of many ExPEC-associ-
ated virulence genes among the ST131 isolates, a significantly
greater proportion of ST131 isolates than non-ST131 isolates ful-
filledmolecular criteria for ExPEC, regardless of CTX-M-15 status
(Table 3). Furthermore, among ST131 (but not non-ST131) iso-
lates, CTX-M-15 was positively associated with ExPEC status.
Thus, of the 4 subgroups, the CTX-M-15-positive ST131 isolates
were the most likely to qualify as ExPEC (94%). Likewise, aggre-
gate virulence scores were significantly greater among ST131 iso-
lates compared with non-ST131 isolates and were greatest of all
within the CTX-M-15-positive ST131 subgroup (see Table 5).
According to PCoA, which was used to summarize the total viru-
lencegenedata set for a simplifiedcomparisonamongsubgroups, the
ST131 isolates and non-ST131 isolates were clearly separated on the
coordinate 1-coordinate 2 plane (Fig. 1). In contrast, among ST131
and non-ST131 isolates alike, CTX-M-15-positive andCTX-M-neg-
ative isolates were largely intermingled, without obvious differences.
AMOVA indicated that 43% of the total variance was among popu-
lations, whereas 57%was within populations.
Antimicrobial resistance profiles.Within the 200-isolate sub-
set, resistance to each tested antimicrobial agent except imipenem
was detected in1 isolate (Table 4). Significant resistance preva-
lence differences among the 4 isolate subgroups, as defined by
combined ST131 and CTX-M-15 status, were noted for 13 agents.
Compared with CTX-M-15-negative isolates, CTX-M-15-posi-
tive isolates had a significantly higher prevalence of resistance to
multiple -lactam agents, regardless of ST131 status, but a signif-
icantly lower prevalence of resistance to streptomycin (if non-
ST131) or sulfonamides (if ST131). In contrast, ST131 and non-
ST131 isolates exhibited comparatively few significant resistance
prevalence differences for -lactam agents, but non-ST131 iso-
lates (especially if CTX-M-15 positive) exhibited a significantly
greater prevalence of resistance to numerous non--lactamagents
(Table 4). Accordingly, aggregate resistance scores, although dif-
fering only slightly among the 4 subgroups, were highest among
the CTX-M-15-positive non-ST131 isolates (median, 15) and
lowest among the CTX-M-15-negative ST131 isolates (median,
12) (Table 5).
In a PCoA based on the 21 studied antimicrobial agents, con-
siderable diversity of aggregate resistances profiles was evident
from the overall spread of points on the coordinate 1-coordinate 2
plane (Fig. 1). However, the 4 subgroups as defined by combined
CTX-M-15 status and ST131 status were considerably intermin-
gled, without obvious among-subgroup differences. According to
AMOVA, only 9% of total variance was among populations; fully
91% was within populations.
PFGE. All but two of the 200 selected isolates yielded interpre-
table XbaI PFGE profiles. The 94% similarity criterion resolved
122 pulsotypes, each containing from 1 isolate (99 pulsotypes) to
27 isolates (1 pulsotype [type 968]). Twenty-three pulsotypes con-
tainedmultiple isolates (99 isolates total); of these, 5 contained5
isolates each (51 isolates total). Membership in a multiple-isolate
pulsotype was significantly associated with both blaCTX-M-15 (re-
gardless of ST131 status) and ST131 (regardless of blaCTX-M-15
status) (Table 3). Similarly,membership in a high-prevalence (5
isolates) pulsotype was confined to ST131 isolates, and among
ST131 isolates it was significantly associated with blaCTX-M-15 sta-
tus (Table 3) and ExPEC status (92% ExPEC for high-frequency
pulsotypes versus 67%; P 0.002).
DISCUSSION
In this analysis of ESBL-positive E. coli isolates from across the
United States (collected in 2000 to 2009), we defined the overall,
by-center, and temporal prevalences of blaCTX-M-15 and ST131,
identified associations of these two traits with one another and
with virulence genotype and resistance profiles, and assessed the
clonal structures of the populations.Ourfindings extend the results
of apreviousnational survey (8) andoffernovel insights into thebasis
for the striking epidemiological success of bothblaCTX-M-15 andE. coli
ST131 strains.
We found a marked predominance of both blaCTX-M-15 and
ST131 among ESBL-producing E. coli isolates collected across the
United States and a very strong (albeit incomplete) association of
these two traits with one another. This confirms, in a very different
study population, the findings of a previous, smaller, single-year na-
FIG 1 Principal coordinate analysis of virulence genotype data (upper panel)
and antimicrobial resistance data (lower panel) among 200 Escherichia coli
isolates (collected in 2000 to 2009) in relation to ST131 and blaCTX-M-15 status.
Populations 1 to 4 correspond to the groups shown in the tables (i.e., Table 1,
non-ST131 blaCTX-M-15 negative; Table 2, non-ST131 blaCTX-M-15 positive; Ta-
ble 3, ST131 blaCTX-M-15 negative; Table 4, ST131 blaCTX-M-15 positive). Upper
panel (virulence genotypes): coordinates 1 and 2 capture 58% and 12%of total
variation, respectively. Note the marked separation of (overlapping) popula-
tions 1 and 2 from (overlapping) populations 3 and 4. Lower panel (antimi-
crobial resistance): coordinates 1 and 2 capture 32% and 26% of total varia-
tion, respectively. Note the marked overlap of all four populations.
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tional survey (8). Notably, both blaCTX-M-15 and ST131 occurred at
each of the 15 participating centers, representing evidence of wide-
spread distribution, but with by-center prevalence differences sug-
gesting possible geographical or host-group specificity.
A novel finding in the present study was that both blaCTX-M-15
and ST131 appeared to have emerged and expanded in distribu-
tion during the past decade, since they were both significantly
more prevalent from 2004 onward. Likewise, both occurred
among isolates from children and adults alike. The somewhat
lower overall prevalences of blaCTX-M-15 and ST131 in the present
study (57% and 47%, respectively), compared with the previous
national survey (78% and 67%, respectively) (8), may reflect in
part the present study’s inclusion of “all-comer” and pediatric
isolates from 2000 through 2009, compared with the previous
survey’s focus on blood isolates from adults from 2007.
Our findings provide insights into possible reasons for the
striking epidemiological success of blaCTX-M-15 and ST131 and
their association with one another. First, despite the obvious hor-
izontal mobility of blaCTX-M-15 (as demonstrated by its occurrence
in diverse phylogenetic backgrounds), blaCTX-M-15 showed evi-
dence of clonal spread and expansion. That is, among the non-
ST131 isolates, blaCTX-M-15 was concentrated within major phylo-
genetic groups A and D and within high-prevalence pulsotypes
within those groups. Similarly, among ST131 isolates, blaCTX-M-15
was significantly associated with the highest-prevalence pulso-
types. To what degree blaCTX-M-15 has contributed directly to the
expansion of these lineages, or is an opportunistic hitchhiker
within intrinsically successful clones, warrants further study.
Second, blaCTX-M-15 was significantly associatedwith resistance
to key first-line antimicrobials, notably -lactams and fluoro-
quinolones, and (among non-ST131 isolates) with higher aggre-
gate resistance scores. This predictably would favor expansion of
blaCTX-M-15-containing strains in preference to other ESBL-produc-
ing E. coli strains in the presence of selection pressure from the cor-
responding antimicrobials, which is abundant and likely increasing.
Third, the large molecularly inferred virulence advantage of
ST131 over non-ST131 isolates (regardless of blaCTX-M-15 status)
and, within ST131, the similar (albeit smaller) advantage of
blaCTX-M-15-positive over blaCTX-M-15-negative isolates would
tend to favor expansion of ST131 and, specifically, its blaCTX-M-15-
positive subset. The marked inferred virulence advantage of ST131
strainsmaymore than compensate for theirmodest resistance disad-
vantage compared with other ESBL-producing E. coli strains. In this
regard, the high prevalence of certain ST131 pulsotypes also may re-
late in part to differential virulence, since isolates from high-fre-
quency pulsotypes were significantlymore likely to qualify as ExPEC
thanwere other ST131 isolates (92%versus 67%;P 0.0002). These
highly successful lineages appear to represent an extreme version of
the combined threats of virulence and resistance (22).
Study limitations included the convenience sample (with its
TABLE 4 Antimicrobial resistance phenotypes of 200 selected extended-spectrum--lactamase-producing Escherichia coli isolates (collected in 2000
to 2009) in relation to ST131 and blaCTX-M-15 status
Antimicrobial class Specific agenta
No. (%) of isolates showing resistance to the indicated agent P valueb
ST131M15
(group 1; n 50)
ST131M15
(group 2; n 50)
ST131M15
(group 3; n 50)
ST131M15
(group 4; n 50)
Group 1
vs 2
Group 3
vs 4
Group 1
vs 3
Group 2
vs 4
-Lactams ATM 33 (66) 47 (94) 29 (58) 41 (82) 0.001 0.002
CAZ 35 (70) 47 (94) 34 (68) 39 (78) 0.003 0.04
CRO 44 (88) 50 (100) 39 (78) 48 (96) 0.03 0.02
FEP 11 (22) 27 (54) 11 (22) 30 (60) 0.002 0.001
Quinolones NA 36 (72) 49 (98) 43 (86) 50 (100) 0.001 0.02
CIP 30 (60) 49 (98) 43 (86) 50 (100) 0.001 0.01 0.006
Aminoglycosides CN 23 (46) 31 (62) 25 (50) 17 (34) 0.009
SF 38 (76) 20 (40) 36 (72) 26 (52) 0.001
Phenicols C 23 (46) 14 (28) 8 (16) 2 (4) 0.002 0.002
Tetracyclines TE 45 (90) 44 (88) 30 (60) 38 (76) 0.001
Folate antagonists SF 44 (88) 39 (78) 39 (78) 28 (56) 0.03 0.03
W 36 (72) 39 (78) 32 (64) 23 (46) 0.002
SXT 37 (74) 37 (74) 31 (62) 22 (44) 0.004
a Agents shown are those that yielded P 0.05 in an initial four-way comparison (not shown), plus at least one pairwise comparison (as shown). These included ATM (aztreonam),
C (chloramphenicol), CAZ (ceftazidime), CIP (ciprofloxacin), CN (gentamicin), CRO (ceftriaxone), FEP (cefepime), NA (nalidixic acid), S (streptomycin), SF (sulfonamide), SXT
(trimethoprim-sulfamethoxazole), TE (tetracycline), and W (trimethoprim). Agents to which resistance was detected in1 isolate but without significant by-group prevalence
differences (definition: overall prevalence) included AMK (amikacin: 10%), AML (amoxicillin-clavulanate: 69%), AMP (ampicillin: 100%), FOX (cefoxitin: 19%), F
(nitrofurantoin: 8%), KF (cefazolin: 97%), PIP (piperacillin: 96%), and TZP (piperacillin-tazobactam: 5%). No resistance was detected to IMP (imipenem).
b P values (by Fisher’s exact test, two-tailed) are shown where P 0.05.
TABLE 5 Aggregate virulence and antimicrobial resistance scores of 200 selected extended-spectrum--lactamase-producing Escherichia coli isolates
(collected in 2000 to 2009) in relation to ST131 and blaCTX-M-15 status
Type of
score
Score median (range) P valuea
ST131M15
(group 1; n 50)
ST131M15
(group 2; n 50)
ST131M15
(group 3; n 50)
ST131M15
(group 4; n 50)
Group 1
vs 2
Group 3
vs 4
Group 1
vs 3
Group 2
vs 4
Virulence 4 (0-18) 4 (1-10) 10 (2-13) 10 (6-14) 0.01  0.001  0.001
Resistance 13 (4-19) 15 (7-19) 12 (4-19) 13 (9-17) 0.04 0.003
a P values (Mann-Whitney U test) are shown where P 0.05.
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attendant potential biases), the undefined clinical background of
the isolates, and a lack of information regarding the identity of the
non-CTX-M-15 ESBLs and non-ST131 clonal groups. Strengths
included the large sample size relative to other studies of ESBL-
positive E. coli strains from the United States, long study interval,
broad geographic range, inclusion of pediatric and adult isolates,
and extensive molecular characterization of the isolates.
In summary, in this large molecular-epidemiological analysis of
ESBL-producing E. coli clinical isolates from the United States (col-
lected in 2000 to 2009), we found a predominance of blaCTX-M-15 and
ST131 strains, which were widely dispersed geographically, involved
pediatric as well as adult patients, and increased significantly in prev-
alence during the study period. Both entities were strongly associated
with one another and, especially in combination,with enhancedmo-
lecularly inferred virulence, extensive antimicrobial resistance, and
decreased clonal diversity, suggesting recent clonal expansion and
dissemination. These findings confirm the importance in theUnited
States of the ST131 clonal group and its characteristic blaCTX-M-15
gene, suggest possible reasons for their emergence, and underscore
the need for effective predictive and preventive measures.
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